title: [Determination of urinary markers of proteolysis/fibrinolysis and fibroangiogenesis in the kidney in hypertensive patients].
abstract: OBJECTIVE
  To determine clinical significance of urinary biomarkers of proteolysis/fibrinolysis and fibroangiogenesis in essential hypertension (EH).
  
  
  METHODS
  Examination of the kidneys was made in 71 patients with EH degree 1-3. Renal function was assessed by 24-h albuminuria, calculated glomerular filtration rate (GFR) by Cockroft-Golt. Early signs of renal damage were microalbuminuria--MAU (diurnal albuminuria 30-300 mg/day), reduction of GFR (< 90 ml/min/1.73 m2). EH patients with hypercreatininemia and GFR under 60 ml/min/1.73m2 corresponding to stage III of chronic kidney disease were not included in the study. An additional nephropathy marker was an elevated index of resistance of interlobular renal arteries (RI > 0.65) as shown by dopplerometry. ELISA examined urinary biomarkers of intercellular and cell-matrix interactions in the kidney in EHpatients and healthy controls (n = 12).
  
  
  RESULTS
  MAU was detected in 54 (76%) of 71 EH patients, elevated RI > 0.65--in 37 (52%) patients. Urinary biomarkers of proteolysis/fibrinolysis and fibroangiogenesis were higher in EH patients then in the controls. Urinary excretion of PAI-1, TGF-beta1, VEGF and collagen of type IV in EH patients with MAU was significantly higher than in patients with normoalbuminuria. A strong direct correlation between MAU and the rest above urinary biomarkers was found as well as between urinary excretion of collagen IV and RI. An inverse negative relationship was seen between RI and GFR.
  
  
  CONCLUSIONS
  Renal impairment in EHpatients is a progressive disorder. Each stage of this process has its own clinicodiagnostic markers. Urinary biomarkers ofproteolysis/fibrinolysis and fibroangiogenesis in the kidney are informative for monitoring of early HNP.
authors.forename: M L
authors.initials: ML
authors.lastname: Nanchikeeva
authors.forename: L V
authors.initials: LV
authors.lastname: Kozlovskaia
authors.forename: V V
authors.initials: VV
authors.lastname: Rameev
authors.forename: V V
authors.initials: VV
authors.lastname: Fomin
authors.forename: N M
authors.initials: NM
authors.lastname: Bulanov
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000209:etiology / Q000652:urine*; D015415:Biomarkers / Q000652:urine; D024141:Collagen Type IV / Q000652:urine; D005260:Female; D005342:Fibrinolysis; D005919:Glomerular Filtration Rate; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000503:physiopathology*; D007674:Kidney Diseases / Q000209:etiology / Q000652:urine*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009389:Neovascularization, Pathologic / Q000209:etiology / Q000652:urine*; D017395:Plasminogen Activator Inhibitor 1 / Q000652:urine; D016212:Transforming Growth Factor beta / Q000652:urine; D042461:Vascular Endothelial Growth Factor A / Q000652:urine; D055815:Young Adult
chemical_list: D015415:Biomarkers; D024141:Collagen Type IV; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D016212:Transforming Growth Factor beta; D042461:Vascular Endothelial Growth Factor A